글로벌 신경 조절 장치 시장 – 2031년까지의 산업 동향 및 예측

신경 조절 장치 시장 분석 및 규모

전 세계적으로 파킨슨병 유병률의 급증은 시장 성장을 촉진하는 주요 요인 중 하나입니다. 의료 기술 발전에 대한 집중 증가와 임상 시험 의 증가 는 또 다른 시장 성장 결정 요인입니다. 의료 관광의 증가와 신경 자극기의 승인율의 급증은 수익성 있는 시장 성장 기회를 더욱 창출할 것입니다.

그러나 장비와 관련된 높은 비용은 시장 성장률을 탈선시킬 것입니다. 의료 전문가 부족과 특히 개발도상국과 저개발국 경제에서 불리한 환불 정책은 시장에 더 큰 과제를 안겨줄 것입니다. 또한 후진 경제권에서의 인식 부족과 신흥 경제권에서의 낮은 진단 및 치료율은 시장 성장률을 저해할 것입니다.             

Data Bridge Market Research는 2023년에 67억 달러였던 글로벌 신경 조절 장치 시장이 2031년까지 163억 7천만 달러에 도달할 가능성이 높으며 예측 기간 동안 11.80%의 CAGR을 경험할 것으로 분석했습니다. "내부 신경 조절"은 내부 신경 조절이 강점과 견고성을 제공하기 때문에 시장의 제품 유형 세그먼트를 지배합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

신경 조절 장치 시장 범위 및 세분화

시장 정의

신경 조절 장치는 신체의 전기 또는 화학 물질을 사용하여 신경 부위를 자극하는 신경 조절 과정에서 사용되는 의료 기기입니다. 신경 조절은 간질, 알츠하이머병 , 뇌혈관 질환 및 파킨슨병과 같은 광범위한 신경 질환을 치료하는 데 사용됩니다.

글로벌 신경 조절 장치 시장 역학

운전자

• 만성 질환의 유병률 증가

만성 통증, 신경 장애, 운동 장애와 같은 만성 질환의 증가는 시장의 중요한 원동력입니다. 척수 자극 및 심부 뇌 자극 을 포함한 신경 조절 요법은 기존의 약물적 접근 방식에 잘 반응하지 않는 환자에게 대체 치료 옵션을 제공합니다.

• 신경 조절 기술의 발전

신경 조절 기술에 대한 지속적인 연구 및 개발은 시장 성장에 기여합니다. 장치 설계, 전극 기술 및 자극 매개변수의 혁신은 신경 조절 요법의 효과와 안전성을 향상시킵니다. 진보는 보다 타겟화되고 정확한 장치의 개발로 이어져 치료 가능한 질환의 범위를 확대할 수 있습니다.

• 신경 조절 요법에 대한 인식 및 수용 증가

의료 전문가와 환자 모두 신경 조절 요법의 이점에 대한 인식이 커지면서 시장이 확대되고 있습니다. 이러한 요법의 효능과 안전성을 뒷받침하는 임상적 증거가 늘어나면서 의사와 환자의 수용이 증가할 가능성이 큽니다. 환자 교육 이니셔티브와 의료 제공자와 기기 제조업체 간의 협업도 신경 ​​조절 기기 도입을 촉진하는 데 중요한 역할을 합니다.

• 의료 시설에 대한 투자 증가

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expanding Applications and Indications

There is an opportunity to explore and develop new applications and indications for neuromodulation devices. As the understanding of neural circuitry and the mechanisms of various disorders improves, neuromodulation therapies can be adapted for a broader range of conditions. Research and development efforts that expand the scope of neuromodulation to address conditions beyond chronic pain, such as psychiatric disorders and autoimmune diseases, could open new markets and revenue streams.

• Technological Innovations and Miniaturization

Continued advancements in technology, including miniaturization and the development of more sophisticated and targeted devices, present opportunities in the neuromodulation devices market. Smaller, implantable devices with enhanced capabilities may lead to increased patient acceptance, improved outcomes, and expanded applications. Innovations such as closed-loop systems that provide adaptive, real-time adjustments based on physiological feedback offer promising prospects for more effective and personalized treatments.

Restraints

• High Cost of Neuromodulation Devices

The cost of neuromodulation devices, including the initial implantation procedure and ongoing maintenance, can be substantial. This poses a challenge for widespread adoption, especially in regions with limited healthcare budgets or where reimbursement policies may not adequately cover the expenses. The high cost can be a barrier to access for some patients and limit market growth.

• Stringent Regulatory Approval Processes

The regulatory approval process for neuromodulation devices is often stringent and time-consuming. Obtaining approvals from regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) involves extensive clinical trials and data submission. Delays in obtaining approvals can hinder the timely introduction of new devices to the market, affecting innovation and competitiveness.

Challenges

• Risk of Adverse Events and Complications

Neuromodulation procedures, like any surgical intervention, carry inherent risks of adverse events and complications. These may include infection, device malfunction, or unintended side effects. Concerns about the safety and long-term outcomes of neuromodulation therapies can impact patient and physician confidence, potentially leading to hesitancy in adopting these treatments.

• Limited Awareness and Understanding

Despite the potential benefits of neuromodulation therapies, there is often limited awareness and understanding among patients and even some healthcare professionals. This lack of awareness can result in underdiagnosis and underutilization of neuromodulation devices for treating certain conditions. Educational efforts are needed to increase awareness about the efficacy, safety, and appropriateness of neuromodulation therapies for various disorders.

This neuromodulation devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neuromodulation devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2023, PathMaker Neurosystems Inc. started a human clinical trial for its MyoRegulator device developed for the treatment of amyotrophic lateral sclerosis (ALS)
• In July 2023, Slavia BioElectronics reported the first implantation of its paper-thin neuromodulation bioelectronic foils for the treatment of severe migraine and cluster headaches

Global Neuromodulation Devices Market Scope

The neuromodulation devices market is segmented on the basis of product type, end user, application and biomaterial. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Internal Neuromodulation
• External Neuromodulation

Application                                                                     

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Repetitive Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

End user

• Hospitals
• Clinics
• Home Healthcare
• Others

Biomaterial

• Metallic Biomaterials
• Polymeric Biomaterials
• Ceramic Biomaterials

Global Neuromodulation Devices Market Regional Analysis/Insights

The neuromodulation devices market is analyzed and market size insights and trends are provided by country, product type, end user, application and biomaterial as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the prevalence of favourable reimbursement policies. Asia-Pacific is expected to exhibit the highest growth rate during the forecast period due to the growth and expansion of healthcare industry in this region, ever-rising geriatric population and growth in the number of neurological disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The neuromodulation devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for neuromodulation devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the neuromodulation Devices market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Neuromodulation Devices Market Share Analysis

The neuromodulation devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neuromodulation devices market.

Some of the major players operating in the neuromodulation devices market are:

• Medtronic (Ireland)
• Boston Scientific Corporation (U.S.)
• Stryker (U.S.)
• Abbott (U.S.)
• B. Braun Melsungen AG (Germany)
• NEVRO CORP. (U.S.)
• NeuroSigma, Inc. (U.S.)
• NeuroPace, Inc. (U.S.)
• Soterix Medical Inc. (U.S.)
• Synapse Biomedical Inc. (U.S.)
• ReShape Lifesciences, Inc. (U.S.)
• 바이오네스 주식회사 (미국)
• ALEVA NEUROTHERAPEUTICS SA(스위스)
• 리바노바 PLC(영국)
• 신경학. (미국)
• 사이버로닉스 주식회사(미국)
• Neuromod(아일랜드)
• Axonics, Inc. (미국)
• Magstim Company Limited(영국)
• Sooma Medical(핀란드)

SKU-47959